Meyns Bart, Jashari Ramadan, Gewillig Marc, Mertens Luc, Komárek Arnost, Lesaffre Emmanuel, Budts Werner, Daenen Willem
Department of Cardiac Surgery, University Hospital Gasthuisberg, Herestraat 49, 3000 Leuven, Belgium.
Eur J Cardiothorac Surg. 2005 Aug;28(2):211-6; discussion 216. doi: 10.1016/j.ejcts.2005.03.041.
To determine the life span of cryopreserved homografts implanted in the right ventricular outflow tract and the factors influencing it.
From 1989 through 2003, we reconstructed the pulmonary valve with 301 homografts in 272 patients (median age 13 years; range 4 days-69 years). Indications were tetralogy of Fallot (136), truncus (23), Rastelli repair (11), double outlet ventricle (13), endocarditis (5), and the Ross operation (84). Median follow-up was 5.7 years (range 0-14). We analyzed possible predictors of graft replacement by simple and multiple Cox regression.
Actuarial survival was 96+/-1.2% at 1, 95+/-1.4% at 5, and 94+/-1.5% at 10 years follow-up. Three homografts were explanted because of endocarditis (excluded from the analysis). Freedom from explantation was 99.6+/-0.4% at 1, 94.5+/-1.7% at 5, and 81.8+/-4.1% at 10 years. Variables, significantly related to explantation in the univariate analysis, were younger age, small graft size, implantation in a non-anatomical position, the aortic donor homograft, a shorter aortic cross-clamp time and the implantation of a second homograft. In the multiple model, non-anatomical position (P=0.001), smaller graft size (P<0.0001) or younger age (on square root scale, P<0.0001) and clamp time (P=0.01) remain as independent risk factors. Immunological variables, like blood group incompatibility, implantation of a second homograft and short warm ischemic time were not significant.
The life span of a cryopreserved homograft is determined by graft size (correlates with age) and the non-anatomic position (correlates with indication). In a specific patient, the second homograft performs as well as the first.
确定植入右心室流出道的冷冻保存同种异体移植物的寿命及其影响因素。
1989年至2003年期间,我们用301个同种异体移植物为272例患者(年龄中位数13岁;范围4天至69岁)进行了肺动脉瓣重建。适应症包括法洛四联症(136例)、永存动脉干(23例)、Rastelli修复术(11例)、双出口心室(13例)、心内膜炎(5例)和Ross手术(84例)。随访时间中位数为5.7年(范围0至14年)。我们通过单因素和多因素Cox回归分析了移植物置换的可能预测因素。
随访1年时精算生存率为96±1.2%,5年时为95±1.4%,10年时为94±1.5%。3个同种异体移植物因心内膜炎而被取出(排除在分析之外)。1年时免于取出的比例为99.6±0.4%,5年时为94.5±1.7%,10年时为81.8±4.1%。在单因素分析中,与取出显著相关的变量包括年龄较小、移植物尺寸小、植入非解剖位置、主动脉供体同种异体移植物、主动脉交叉阻断时间较短以及植入第二个同种异体移植物。在多因素模型中,非解剖位置(P = 0.001)、移植物尺寸较小(P < 0.0001)或年龄较小(以平方根尺度衡量,P < 0.0001)以及阻断时间(P = 0.01)仍然是独立的危险因素。免疫相关变量,如血型不相容、植入第二个同种异体移植物和短热缺血时间并不显著。
冷冻保存同种异体移植物的寿命由移植物尺寸(与年龄相关)和非解剖位置(与适应症相关)决定。在特定患者中,第二个同种异体移植物的性能与第一个相同。